NPC1L1 and coronary artery disorder: An examination of the GLGC dataset employing the IVW method revealed that PCSK9, HMGCR, and NPC1L1 inhibitors significantly mitigated the risk of CHD (OR [95%CI] =0.60 [0.46-0.74], p<0.001; OR [95%CI] =0.69 [0.54-0.84], p<0.001, respectively) (OR [95%CI] =0.60 [0.28-0.92], p=2.1×10^-3) (Figure 3), (Supplementary Files S1-S5).